Cedars Sinai

Is TAVR appropriate for patients with bicuspid valves?

Researchers have developed a new online tool designed to help patients with inflammatory bowel disease navigate different options for biologic therapy and decide which one would work best for them, according to a study published in the American Journal of Gastroenterology’s “Putting Patients First” special issue.

In his long career as a gastroenterologist, Stephen R. Targan, MD, has seen many innovations and treatments emerge in his field.  But, throughout these changes over 30 years, one guiding principle has remained the same.

The number of tweets that came out of the American Society of Breast Surgeons Annual Meeting between 2013 and 2016 increased by 600%, according to results published in the Annals of Surgical Oncology.

The Bruce and Cynthia Sherman Charitable Foundation has announced the 2017 recipients of the Sherman Prize for their research in the treatment of Crohn’s disease and ulcerative colitis.

Primary nonresponse to anti-TNF therapy was more likely in patients with inflammatory bowel disease with certain colonic phenotypes, according to new research. These predictors could be used to help personalize IBD management.

CHICAGO — Aldoxorubicin monotherapy appeared well tolerated and may improve outcomes compared with standard treatments for relapsed/refractory soft tissue sarcoma, according to results of a phase 3 clinical trial presented at the ASCO Annual Meeting.

CHICAGO — In this exclusive video from Digestive Disease Week, Mark Pimentel, MD, executive director of the Medically Associated Science and Technology program at Cedars Sinai Medical Center in Los Angeles, discusses new developments in understanding the relationship between irritable bowel syndrome and the gut microbiome, and specifically developments in breath testing and emerging microbiome therapeutics shared at the meeting.

A study of social media posts showed patients with inflammatory bowel disease more often share their concerns about the negative side effects of biologics rather than their benefits or costs, leading investigators to conclude that physicians should do more to help patients understand their treatment options.

CHICAGO — In this exclusive video from Digestive Disease Week, Mark Pimentel, MD, executive director of the Medically Associated Science and Technology program at Cedars Sinai, discusses his research on predicting response to Xifaxan in patients with irritable bowel syndrome.